UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 53

Sortiert nach

Trial in Progress: A Phase 1b/2 Study of GB5121, a Brain-Penetrant, Potent, Highly Selective, and Irreversible BTK Inhibitor for Relapsed/Refractory Primary/Secondary CNS Lymphoma and Primary Vitreoretinal Lymphoma

Blood, 2022-11, Vol.140 (Supplement 1), p.12068-12069

2022

Volltextzugriff (PDF)

Safety, Tolerability, and Pharmacokinetic Profile of Single and Multiple Ascending Doses of GB5121, a CNS-Penetrant BTK Inhibitor, in Healthy Subjects

Blood, 2022-11, Vol.140 (Supplement 1), p.11570-11571

2022

Volltextzugriff (PDF)

The Binding of Bovine Factor XII to Kaolin

Blood, 1983-04, Vol.61 (4), p.652-659

McDevitt, Edward P. Kirby and Patrick J.

1983

Volltextzugriff (PDF)

The GATA factor revolution in hematology

Blood, 2017-04, Vol.129 (15), p.2092-2102

2017

Volltextzugriff (PDF)

Face Validity of the Kid's ITP Tools (KIT) in the Era of Thrombopoietin Receptor Agonists (TPO-RAs)

Blood, 2022-11, Vol.140 (Supplement 1), p.13152-13153

2022

Volltextzugriff (PDF)

Context-dependent function of “GATA switch” sites in vivo

Blood, 2011-05, Vol.117 (18), p.4769-4772

2011

Volltextzugriff (PDF)

Evaluating the Impact of Thrombopoietin Receptor Agonists Medications on Patient Outcomes and Quality of Life in Pediatric Immune Thrombocytopenia

Blood, 2021-11, Vol.138 (Supplement 1), p.4072-4072

2021

Volltextzugriff (PDF)

Liberation of ATP secondary to hemolysis is not mutually exclusive of regulated export

Blood, 2015-03, Vol.125 (11), p.1844-1845

2015

Volltextzugriff (PDF)

Development of Anti-CD45 Antibody Drug Conjugates As Targeted Conditioning Agents for Transplantation/Gene Therapy with Potent Anti-Leukemic Properties

Blood, 2022-11, Vol.140 (Supplement 1), p.10211-10212

2022

Volltextzugriff (PDF)

Modeling Relapsed, Refractory Acute Lymphoblastic Leukemia from a Child with Neurofibromatosis

Blood, 2021-11, Vol.138 (Supplement 1), p.1317-1317

2021

Volltextzugriff (PDF)

Hmgb3: an HMG-box family member expressed in primitive hematopoietic cells that inhibits myeloid and B-cell differentiation

Blood, 2003-08, Vol.102 (4), p.1298-1306

2003

Volltextzugriff (PDF)

CFT7455, a Novel IKZF1/3 Degrader, Demonstrates Potent Anti-Tumor Activity in Models of Non-Hodgkin's Lymphoma As a Single Agent or in Combination with Clinically Approved Agents

Blood, 2022-11, Vol.140 (Supplement 1), p.11575-11575

2022

Volltextzugriff (PDF)

Loss-of-Function and Gain-of-Function Consequences of GATA2 Disease Mutations

Blood, 2019-11, Vol.134 (Supplement_1), p.2519-2519

2019

Volltextzugriff (PDF)

GATA2-Dependent Developmental and Regenerative Networks

Blood, 2019-11, Vol.134 (Supplement_1), p.1182-1182

2019

Volltextzugriff (PDF)

Increasing Incidence and Prevalence of Pathologic Hemoglobinopathies Among Children in Ontario, Canada from 1991-2013

Blood, 2018-11, Vol.132 (Supplement 1), p.4698-4698

2018

Volltextzugriff (PDF)

KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice

Blood, 2012-02, Vol.119 (6), p.1511-1521

2012

Volltextzugriff (PDF)

Data Access and Interactive Visualization of Whole Genome Sequence of Sickle Cell Patients within the St. Jude Cloud

Blood, 2018-11, Vol.132 (Supplement 1), p.723-723

2018

Volltextzugriff (PDF)

Mouse Modeling of GATA2 Related MDS/AML

Blood, 2015-12, Vol.126 (23), p.2855-2855

2015

Volltextzugriff (PDF)

Factors Impacting Quality of Life in Thalassemia Patients; Results from the Intercontinenthal Collaborative Study

Blood, 2016-12, Vol.128 (22), p.3633-3633

2016

Volltextzugriff (PDF)

Genotype/Phenotype Correlations in 103 Children from 87 Families with Hereditary Spherocytosis

Blood, 2016-12, Vol.128 (22), p.2432-2432

2016

Volltextzugriff (PDF)

Bone Marrow Failure and Developmental Delay Caused By Mutations in Poly(A)-Specific Ribonuclease

Blood, 2015-12, Vol.126 (23), p.2404-2404

2015

Volltextzugriff (PDF)

A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous Leukemia (AML)

Blood, 2014-12, Vol.124 (21), p.118-118

2014

Volltextzugriff (PDF)

1 – 25 von 53

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieBlood

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(53)
Mit Volltextzugriff
(53)

Publikationsform

Artikel
(53)

Sprache

Englisch
(53)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Hematology
(17)
Life Sciences & Biomedicine
(17)
Science & Technology
(17)
Humans
(14)
Biological And Medical Sciences
(13)
Medical Sciences
(11)
Animals
(10)
Hematologic And Hematopoietic Diseases
(8)
Anemias. Hemoglobinopathies
(5)
Diseases Of Red Blood Cells
(5)
Mice
(5)
Child
(4)
Hematopoietic Stem Cells - Metabolism
(4)
Anemia, Sickle Cell - Blood
(3)
Female
(3)
Male
(3)
Mice, Inbred C57bl
(3)
Mice, Transgenic
(3)
Acquired Immunodeficiency Syndrome - Blood
(2)
Adolescent
(2)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Menü

Weitere Dienste

Einstellungen

Trial in Progress: A Phase 1b/2 Study of GB5121, a Brain-Penetrant, Potent, Highly Selective, and Irreversible BTK Inhibitor for Relapsed/Refractory Primary/Secondary CNS Lymphoma and Primary Vitreoretinal Lymphoma

Safety, Tolerability, and Pharmacokinetic Profile of Single and Multiple Ascending Doses of GB5121, a CNS-Penetrant BTK Inhibitor, in Healthy Subjects

The Binding of Bovine Factor XII to Kaolin

The GATA factor revolution in hematology

Face Validity of the Kid's ITP Tools (KIT) in the Era of Thrombopoietin Receptor Agonists (TPO-RAs)

Context-dependent function of “GATA switch” sites in vivo

Evaluating the Impact of Thrombopoietin Receptor Agonists Medications on Patient Outcomes and Quality of Life in Pediatric Immune Thrombocytopenia

Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure

Liberation of ATP secondary to hemolysis is not mutually exclusive of regulated export

Development of Anti-CD45 Antibody Drug Conjugates As Targeted Conditioning Agents for Transplantation/Gene Therapy with Potent Anti-Leukemic Properties

Modeling Relapsed, Refractory Acute Lymphoblastic Leukemia from a Child with Neurofibromatosis

Hmgb3: an HMG-box family member expressed in primitive hematopoietic cells that inhibits myeloid and B-cell differentiation

CFT7455, a Novel IKZF1/3 Degrader, Demonstrates Potent Anti-Tumor Activity in Models of Non-Hodgkin's Lymphoma As a Single Agent or in Combination with Clinically Approved Agents

Loss-of-Function and Gain-of-Function Consequences of GATA2 Disease Mutations

GATA2-Dependent Developmental and Regenerative Networks

Increasing Incidence and Prevalence of Pathologic Hemoglobinopathies Among Children in Ontario, Canada from 1991-2013

KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice

Data Access and Interactive Visualization of Whole Genome Sequence of Sickle Cell Patients within the St. Jude Cloud

Mouse Modeling of GATA2 Related MDS/AML

Factors Impacting Quality of Life in Thalassemia Patients; Results from the Intercontinenthal Collaborative Study

Genotype/Phenotype Correlations in 103 Children from 87 Families with Hereditary Spherocytosis

Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury

A Phase 1b Study of Venetoclax (ABT-199/GDC-0199) in Combination with Decitabine or Azacitidine in Treatment-Naive Patients with Acute Myelogenous Leukemia Who Are ≥ to 65 Years and Not Eligible for Standard Induction Therapy

Bone Marrow Failure and Developmental Delay Caused By Mutations in Poly(A)-Specific Ribonuclease

A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous Leukemia (AML)

Aktive Filter

Suchergebnisse filtern